发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Lilly's obesity pill records modest second week as battle with Novo intensifies
发布时间
167 天前
2026-04-24 12:14:06 UTC
源站更新
167 天前
2026-04-24 17:52:36 UTC
首次抓取
167 天前
2026-04-24 18:06:58 UTC
礼来公司新推出的口服减肥药 Foundayo 在上市第二周录得 3707 份处方，表现不及分析师预期，且远低于竞争对手诺和诺德 Wegovy 口服药同期表现。受此影响，礼来股价下跌约 4%，而诺和诺德股价上涨。
Eli Lilly's new weight-loss pill, Foundayo, recorded 3,707 prescriptions in its second week, trailing significantly behind the 18,410 prescriptions seen during the second week of rival Novo Nordisk's oral Wegovy launch. Analysts described the uptake as modest, leading to a 4%
用于追踪这条内容的来源与记录标识。
